Document is current
Any future updates will be listed below
-
Authors
Breyer, Marie-Kathrin https://orcid.org/0000-0003-2086-8483
Breyer-Kohansal, Robab
Hartl, Sylvia
Kundi, Michael
Weseslindtner, Lukas
Stiasny, Karin
Puchhammer-Stöckl, Elisabeth
Schrott, Andrea
Födinger, Manuela
Binder, Michael
Fiedler, Markus
Wouters, Emiel F. M.
Burghuber, Otto C.
-
Funding
Funding for this research was provided by:
Vienna Science and Technology Fund (COVID-19-rapid response)
Medical Scientific Fund of the Mayor of the City of Vienna
- License Information
-
More Information
Article History
Received: 28 January 2021
Accepted: 27 April 2021
First Online: 12 May 2021
Competing interests
: SH reports personal fees from GlaxoSmithKline Pharma GmbH, Boehringer Ingelheim RCV GmbH & Co KG, Menarini Pharma GmbH, Chiesi Pharmaceuticals GmbH, AstraZeneca Austria GmbH, Merck Sharp & Dohme, Novartis AG, Hoffman-La Roche AG, Takeda Pharma, AbbVie, Teva Pharmaceutical Industries Limited, outside the submitted work. KS reports a research grant from Pfizer Corporation Austria Ges.m.b.H., outside the submitted work. OCB reports grants from Boehringer Ingelheim RCV GmbH & Co KG, GlaxoSmithKline Pharma GmbH, AstraZeneca Austria GmbH, Pfizer Inc., Chiesi Pharmaceuticals GmbH, Novartis AG, and non-financial support from the Viennese Health Association, during the conduct of the original LEAD study; Personal fees from Boehringer Ingelheim RCV GmbH & Co KG, AstraZeneca Austria GmbH, Chiesi Pharmaceuticals GmbH, Merck Sharp & Dohme, A. Menarini Pharma GmbH, Hoffman-La Roche AG, GlaxoSmithKline Pharma GmbH, Takeda Pharma, outside the submitted work. All authors declare no competing interest.
